We evaluated the number, viability and kinetic of CD109+CECs and of CD146+ CECs and observed that both subpopulation of endothelial cells are enriched in the blood of glioblastoma and breast cancer patients, are more viable when compared to value observed in healthy subject, and their number decrease significantly after treatment. The gene discussed is CD109; the disease is breast cancer.